Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Dis Esophagus ; 33(10)2020 Oct 12.
Artigo em Inglês | MEDLINE | ID: mdl-32115648

RESUMO

There is debate surrounding the appropriate threshold for lymph node harvest during esophagectomy in patients with esophageal cancer, specifically for those receiving preoperative radiation. The purpose of this study was to determine the impact of lymph node yield on survival in patients receiving preoperative chemoradiation for esophageal cancer. The National Cancer Database (NCDB) was utilized to identify patients with esophageal cancer that received preoperative radiation. The cohort was divided into patients undergoing minimal (<9) or extensive (≥9) lymph node yield. Demographic, operative, and postoperative outcomes were compared between the groups. Kaplan-Meier analysis with the log rank test was used to compare survival between the yield groups. Cox proportional hazards model was used to determine the association between lymph node yield and survival. In total, 886 cases were included: 349 (39%) belonging to the minimal node group and 537 (61%) to the extensive group. Unadjusted 5-year survival was similar between the minimal and extensive groups, respectively (37.3% vs. 38.8%; P > 0.05). After adjustment using Cox regression, extensive lymph node yield was associated with survival (hazard ratio 0.80, confidence interval 0.66-0.98, P = 0.03). This study suggests that extensive lymph node yield is advantageous for patients with esophageal cancer undergoing esophagectomy following induction therapy. This most likely reflects improved diagnosis and staging with extensive yield.


Assuntos
Neoplasias Esofágicas , Excisão de Linfonodo , Neoplasias Esofágicas/patologia , Neoplasias Esofágicas/cirurgia , Esofagectomia , Esôfago/patologia , Humanos , Linfonodos/patologia , Estadiamento de Neoplasias , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Taxa de Sobrevida
2.
J Med Primatol ; 47(1): 81-84, 2018 02.
Artigo em Inglês | MEDLINE | ID: mdl-28671309

RESUMO

Recrudescence of latent and dormant viruses may lead to overwhelming viremia in immunosuppressed hosts. In immunocompromised hosts, Simian virus 40 (SV40) reactivation is known to cause nephritis and demyelinating central nervous system disease. Here, we report SV40 viremia leading to fatal interstitial pneumonia in an immunosuppressed host following renal allotransplantation.


Assuntos
Hospedeiro Imunocomprometido , Nefropatias/fisiopatologia , Macaca mulatta , Doenças dos Macacos/fisiopatologia , Pneumonia/fisiopatologia , Infecções por Polyomavirus/veterinária , Vírus 40 dos Símios/fisiologia , Infecções Tumorais por Vírus/veterinária , Animais , Nefropatias/virologia , Transplante de Rim/veterinária , Doenças dos Macacos/virologia , Pneumonia/virologia , Infecções por Polyomavirus/complicações , Infecções Tumorais por Vírus/complicações
3.
Am J Transplant ; 17(5): 1193-1203, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-27888551

RESUMO

Costimulation blockade (CoB) via belatacept is a lower-morbidity alternative to calcineurin inhibitor (CNI)-based immunosuppression. However, it has higher rates of early acute rejection. These early rejections are mediated in part by memory T cells, which have reduced dependence on the pathway targeted by belatacept and increased adhesion molecule expression. One such molecule is leukocyte function antigen (LFA)-1. LFA-1 exists in two forms: a commonly expressed, low-affinity form and a transient, high-affinity form, expressed only during activation. We have shown that antibodies reactive with LFA-1 regardless of its configuration are effective in eliminating memory T cells but at the cost of impaired protective immunity. Here we test two novel agents, leukotoxin A and AL-579, each of which targets the high-affinity form of LFA-1, to determine whether this more precise targeting prevents belatacept-resistant rejection. Despite evidence of ex vivo and in vivo ligand-specific activity, neither agent when combined with belatacept proved superior to belatacept monotherapy. Leukotoxin A approached a ceiling of toxicity before efficacy, while AL-579 failed to significantly alter the peripheral immune response. These data, and prior studies, suggest that LFA-1 blockade may not be a suitable adjuvant agent for CoB-resistant rejection.


Assuntos
Abatacepte/farmacologia , Rejeição de Enxerto/tratamento farmacológico , Sobrevivência de Enxerto/imunologia , Memória Imunológica/imunologia , Transplante de Rim/efeitos adversos , Antígeno-1 Associado à Função Linfocitária/química , Linfócitos T/imunologia , Animais , Modelos Animais de Doenças , Taxa de Filtração Glomerular , Rejeição de Enxerto/etiologia , Rejeição de Enxerto/patologia , Sobrevivência de Enxerto/efeitos dos fármacos , Memória Imunológica/efeitos dos fármacos , Imunossupressores/farmacologia , Testes de Função Renal , Antígeno-1 Associado à Função Linfocitária/metabolismo , Macaca mulatta , Complicações Pós-Operatórias , Linfócitos T/efeitos dos fármacos , Linfócitos T/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...